About the Company
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. Madrigal recognizes that compounds with greater selectivity for thyroid hormone receptor (THR)-ß and liver uptake has the greatest potential to overcome challenges faced by prior, less selective compounds and deliver the full therapeutic potential of THR-ß agonism. The Company believes that resmetirom, its lead product candidate, is the first orally administered, small-molecule, liver-directed, truly ß-selective THR agonist.
Employees
42
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MDGL News
Madrigal Pharmaceuticals Awards Equity to New Employees as Inducement
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has granted equity awards to 30 new hires under its 2023 Inducement Plan, as a ...
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company ...
Madrigal Pharmaceuticals Inc MDGL
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic ...
Madrigal Pharmaceuticals Launches Rezdiffra, a Pioneer in NASH Treatment
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced the U.S. availability of Rezdiffra (resmetirom ...
Madrigal Pharmaceuticals Announces Proposed Public Offering
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic ...
Madrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 Shares
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), a clinical-stage biopharmaceutical company focusing on the development and ...
Madrigal Pharmaceuticals Inc MDGL
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Madrigal Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...